首页> 外文期刊>Travel medicine and infectious disease >Artemisinin based combination therapy in travel medicine
【24h】

Artemisinin based combination therapy in travel medicine

机译:基于青蒿素的旅行医学联合疗法

获取原文
获取原文并翻译 | 示例
           

摘要

A steadily increasing number of Western travellers are exposed to malaria. Also, numbers of migrants from malarious areas are increasing. Fast and effective treatment options are needed to ensure effective malaria treatment in these groups in the future. Artemisinin combinations are well tolerated and have shown high efficacy in malaria endemic areas. Since 2001, 42 malaria endemic countries, 23 of them in Africa, have adopted artemisinin based combination therapies recommended by WHO. An additional 14 countries are in the process of changing their malaria treatment policy. Studies in non-immune travellers confirm a rapid parasite clearance time and very low rate of side effects. Outpatient clinics and hospitals in non-endemic countries should have standard operating procedures for diagnosing and managing patients with malaria. In this setting, artemisinin combinations should be available for treatment of uncomplicated malaria as they are clearly superior to any other oral antimalarial in their fast reduction of parasite biomass and in decreasing clinical symptoms. Also, they are the drugs of choice for travellers who are advised to carry stand-by emergency treatment during their journey.
机译:不断增加的西方旅行者暴露于疟疾。此外,来自疟疾地区的移民人数也在增加。需要快速有效的治疗方案,以确保将来在这些人群中有效治疗疟疾。青蒿素组合具有良好的耐受性,在疟疾流行地区已显示出高疗效。自2001年以来,有42个疟疾流行国家(其中23个在非洲)采用了WHO推荐的以青蒿素为基础的联合疗法。另有14个国家正在改变其疟疾治疗政策。对非免疫旅行者的研究证实了快速的寄生物清除时间和非常低的副作用率。非流行国家的门诊和医院应具有标准的手术程序,以诊断和管理疟疾患者。在这种情况下,青蒿素组合应可用于治疗单纯性疟疾,因为它们在减少寄生虫生物量和减少临床症状方面明显优于任何其他口服抗疟药。此外,它们还是建议旅客在旅途中进行备用紧急治疗的旅行者的首选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号